An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study of Drug in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sponsor: BeiGene, Ltd.
Enrolling: Male and Female Patients
IRB Number: AAAR6732
U.S. Govt. ID: NCT03336333
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the effects, good or bad, of the experimental drug BGB-3111, versus a known standard treatment called bendamustine plus rituximab (B+R) on you and your chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to find out which is better. In this study, you will receive either BGB-3111 or the standard chemotherapy treatment bendamustine plus rituximab (B+R).
This study is closed
Investigator
Nicole Lamanna, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a diagnosis of CLL or SLL? Yes No
Do you have a life expectancy of at least 6 months? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE